Search results
Results from the WOW.Com Content Network
The U.S. Food and Drug Administration (FDA) notified healthcare professionals of updates to the prescribing information concerning interactions between protease inhibitors and certain statin drugs. Protease inhibitors and statins taken together may increase the blood levels of statins and increase the risk for muscle injury (myopathy).
A drug combination chart designed for harm reduction by TripSit [1] Polysubstance use or multisubstance use is the use of combinations of psychoactive substances with both legal and illegal substances. This page lists polysubstance combinations that are entheogenic, recreational, or off-label indicated use of pharmaceuticals.
Some statins may also alter the concentrations of other medications, such as warfarin or digoxin, leading to alterations in effect or a requirement for clinical monitoring. [56] The increase in digoxin levels due to atorvastatin is a 1.2 fold elevation in the area under the curve (AUC), resulting in a minor
The specificity and the tight binding of statins is due to orientation and bonding interactions that form between the statin and the HMGR enzyme. [9] Polar interactions are formed between the HMG-moiety and residues that are located in the cis loop of the enzyme. These polar interactions are between Ser 684, Asp 690, Lys 691 and Lys 692 (Figure 4).
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
[33] [34] [35] Rosuvastatin 5 mg and 10 mg are examples of regimens meeting the USPSTF guideline; [32] however, insurers have discretion as to which low- and moderate-dose statin regimens to cover under this requirement, [36] and some only cover other statins. [37] The drug was billed as a "super-statin" during its clinical development; the ...
Pitavastatin (usually as a calcium salt) is a member of the blood cholesterol lowering medication class of statins. [1] Pitavastatin is an inhibitor of HMG-CoA reductase, the enzyme that catalyses the first step of cholesterol synthesis. It was patented in 1987 and approved for medical use in 2003. [2] It is available in Japan, South Korea and ...
It is a combination of ezetimibe (known as Zetia in the United States) and the statin drug simvastatin (known as Zocor in the US). Ezetimibe reduces blood cholesterol by acting at the brush border of the small intestine and inhibiting the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver.